IP Library Granted Patent US 7,585,631
Granted Patent B2
US 7,585,631 · App. 11/459,885 · Granted Sep 8, 2009

Method for obtaining purified RNA from viable oocysts

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,585,631
App. No.
11/459,885
Granted
Sep 8, 2009
Kind
B2
Abstract

The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from Crytosporidium organisms, and Crytosporidium parvum organisms in particular, which are useful for determining the presence of Cryptosporidium organisms in a test sample. The oligonucleotides of the present invention include hybridization assay probes, helper probes and amplification primers. The present invention further describes a novel method for obtaining purified ribonucleic acid from viable oocysts.

Claims (21)

1. A method for obtaining purified RNA from viable oocysts, the method comprising the steps of:

a) centrifuging a fluid sample containing oocysts at a speed and for a period of time sufficient to concentrate the oocysts within a vessel containing the fluid sample;

b) removing a supernatant formed in the vessel during the centrifuging step;

c) resuspending the concentrated oocysts in a buffered solution;

d) agitating the buffered solution in the presence of zirconia/silica particles at a rate and for a period of time sufficient to lyse the oocysts and release RNA therefrom;

e) immobilizing the released RNA on an RNA-binding filter;

f) purifying the released RNA by washing the filter one or more times with a buffered solution to remove oocyst components other than the released RNA; and

g) removing the purified RNA from the filter.

2. The method of claim 1 , wherein said oocysts include Cryptosporidium organisms.

3. The method of claim 2 , wherein said Cryptosporidium organisms include Cryptosporidium parvum.

4. The method of claim 1 , wherein said centrifuging step is performed at about 7000 revolutions per minute for approximately 5 minutes.

5. The method of claim 1 , wherein the buffered solution includes a chaotropic agent capable of inactivating endogenous ribonucleases released from the oocysts.

6. The method of claim 5 , wherein the chaotropic agent is guanidinium thiocyanate.

7. The method of claim 1 , wherein the agitating step is performed by oscillating or vortexing the buffered solution.

8. The method of claim 1 , wherein the particles have a density of about 3.7 g/cc.

9. The method of claim 1 , wherein the particles have a generally spherical shape.

10. The method of claim 9 , wherein the particles have an average diameter in the range of about 0.1 to about 2.5 mm.

11. The method of claim 9 , wherein the particles have an average diameter in the range of about 0.5 to about 1 mm.

12. The method of claim 9 , wherein the particles have an average diameter of about 1 mm.

13. The method of claim 1 , wherein the filter is a silica-based matrix.

14. The method of claim 1 , wherein the oocyst components include proteins and DNA.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →